Lightpoint Medical, the UK start-up behind the first technology in the world to detect human cancers in real time using Cerenkov Luminescence Imaging* (CLI), is set to fast-track its move to market with the support of a further £1 million grant from SBRI, an NHS England funded initiative.
The funding boost, along with a recent £2.8 million from Innovate UK, and a combination of angel investment and crowdfunding means that for the first time in medical history, surgeons across the world could be using this pioneering technology to detect cancer in real time in the next 12 months.
As this technology has never been used in the healthcare market before, it is attracting enormous interest from public and private funding sources. Dr David Tuch, CEO, Lightpoint Medical explains, “Our technology is a major breakthrough in cancer surgery; it is not being used anywhere else in the world. The level of grants and funding that Lightpoint Medical has received reflects the real clinical demand for our technology, and its market potential. This latest funding boost will help ensure our products are launched in the US and European markets within the next 12 months.”
Created and manufactured in the UK, Lightpoint Medical is set to change the future of cancer surgery; detecting cancerous tissue and preventing the removal of healthy tissue during surgery, thereby reducing the need for repeat operations.
